rexaceract (GT-02287)

November 5, 2026: Gain Therapeutics, Inc. (NASDAQ: GANX) announced upcoming data presentations for its Parkinson’s disease programs at the 31st IAPRD World Congress and Neuroscience 2026. At IAPRD in Milan (November 11-14, 2026), the company will present a late-breaking guided poster on the open-label extension of a Phase 1b study of rexaceract (GT-02287) in Parkinson’s disease on November 13, and a poster on preclinical development of GT-04686, a novel GCase allosteric modulator, in a GBA1 Parkinson’s disease model.

At Neuroscience 2026 in Washington, D.C. (November 14-18, 2026), Gain will present a poster on November 17 reporting that GT-04686 reduced neuropathology and improved motor and non-motor function in a preclinical model of GBA1 Parkinson’s disease.

The release also states rexaceract is currently being evaluated in a Phase 1b clinical trial for Parkinson’s disease with or without a GBA1 mutation. Upcoming catalysts mentioned include results from the Phase 1b study and any extension studies, and the planned start of a Phase 2 clinical study for rexaceract, though no dates were provided.